CAWM
ALDX icon

Capital Advisors Wealth Management’s Aldeyra Therapeutics ALDX Stock Holding History

Capital Advisors Wealth Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,000
Closed -$25.4K – 232
2026
Q1 		$25.4K Sell
15,000
-800
-5% -$3.5K ﹤0.01% 216
2025
Q4 		$81.8K Buy
15,800
+5,000
+46% +$25.7K 0.01% 215
2025
Q3 		$56.4K Hold
10,800
– – 0.01% 214
2025
Q2 		$41.4K Hold
10,800
– – 0.01% 190
2025
Q1 		$62.1K Buy
+10,800
New +$63.8K 0.01% 179

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Capital Advisors Wealth Management's ALDX Position: Q2 2026 in Review

Capital Advisors Wealth Management sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 15,000 shares — an estimated $25.4K sold.

Capital Advisors Wealth Management first reported a position in ALDX in Q1 2025 and held it in 5 quarters. The position peaked at $81.8K in Q4 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Capital Advisors Wealth Management reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Capital Advisors Wealth Management sold 15,000 Aldeyra Therapeutics shares in Q2 2026, an estimated $25.4K.
  • Capital Advisors Wealth Management first reported a position in Aldeyra Therapeutics in Q1 2025 and held it in 5 quarters.
  • Capital Advisors Wealth Management's Aldeyra Therapeutics position peaked at $81.8K in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Capital Advisors Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.